Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019
AUTHORS
Tenforde
MW ,
Cummings
CN ,
O'Halloran
AC ,
Rothrock
G ,
Kirley
PD ,
Alden
NB ,
Meek
J ,
Yousey-Hindes
K ,
Openo
KP ,
Anderson
EJ ,
Monroe
ML ,
Kim
S ,
Nunez
VT ,
McMahon
M ,
McMullen
C ,
Khanlian
SA ,
Spina
NL ,
Muse
A ,
Gaitán
MA ,
Felsen
CB ,
Lung
K ,
Shiltz
E ,
Sutton
M ,
Thomas
A ,
Talbot
HK ,
Schaffner
W ,
Price
A ,
Chatelain
R ,
Reed
C ,
Garg
S ,
. Open forum infectious diseases. 2022 12 19; 10(1). ofac681
- PMID: 36686630 [PubMed].
ABSTRACT
From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015-2016 through 2018-2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.
Tags: faculty publications 2022